Vanc Pharmaceuticals Receives Health Canada Approval for 22 Generic Molecules
(firmenpresse) - VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 11/18/14 -- Vanc Pharmaceuticals Inc. ("Vanc" or the "Company") (TSX VENTURE: NPH)(OTCQB: NUVPF) is pleased to announce that it has received Notice of Compliance (NOC) from Health Canada for 22 generic molecules. These 22 molecules will comprise of 51 dosage forms across various therapeutic categories; including both chronic (long term) therapy and acute (short term) therapy. The Notice of Compliance from Health Canada provides the authorization for Vanc to market and sell the generic molecules in Canada.
The current aggregate annual Canadian sales of these 22 products is estimated to be approximately $900 million.
"As Western Canada''s first generic drug company we are excited to have made a significant step towards commercializing our brand in the Canadian generics market. Over the coming two quarters we plan to begin manufacturing these products and commence sales and marketing activities in Q2-2015," said Arun Nayyar, CEO of Vanc. "Our aim is to launch with additional products and we will provide further updates in the coming months."
Table 1.0 provides details on each of the molecules.
On behalf of:
Vanc Pharmaceuticals Inc.
Jamie Lewin, Director and CFO
Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves VANC''s expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. VANC generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "plan," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to VANC as of the date of this release, and VANC assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of VANC and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
Vanc Pharmaceuticals Inc.
Jamie Lewin
Director and CFO
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 18.11.2014 - 08:00 Uhr
Sprache: Deutsch
News-ID 1319370
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
VANCOUVER, BRITISH COLUMBIA
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 129 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Vanc Pharmaceuticals Receives Health Canada Approval for 22 Generic Molecules
"
steht unter der journalistisch-redaktionellen Verantwortung von
Vanc Pharmaceuticals Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
